Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2015 1
2017 5
2018 4
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.
Motoyama H, Tamori A, Kubo S, Uchida-Kobayashi S, Takemura S, Tanaka S, Ohfuji S, Teranishi Y, Kozuka R, Kawamura E, Hagihara A, Morikawa H, Enomoto M, Murakami Y, Kawada N. Motoyama H, et al. Among authors: teranishi y. PLoS One. 2018 Mar 13;13(3):e0194163. doi: 10.1371/journal.pone.0194163. eCollection 2018. PLoS One. 2018. PMID: 29534101 Free PMC article.
Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed.
Yoshida K, Hai H, Tamori A, Teranishi Y, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y, Kawada N. Yoshida K, et al. Among authors: teranishi y. Int J Mol Sci. 2017 May 3;18(5):962. doi: 10.3390/ijms18050962. Int J Mol Sci. 2017. PMID: 28467359 Free PMC article.
Changes in plasma interleukin-8 and tumor necrosis factor-α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma.
Iida-Ueno A, Enomoto M, Uchida-Kobayashi S, Hagihara A, Teranishi Y, Fujii H, Morikawa H, Murakami Y, Tamori A, Thuy LTT, Kawada N. Iida-Ueno A, et al. Among authors: teranishi y. Cancer Chemother Pharmacol. 2018 Nov;82(5):857-864. doi: 10.1007/s00280-018-3681-x. Epub 2018 Sep 3. Cancer Chemother Pharmacol. 2018. PMID: 30178114
Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.
Kozuka R, Hai H, Teranishi Y, Motoyama H, Kawamura E, Hagihara A, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y, Kawada N, Tamori A. Kozuka R, et al. Among authors: teranishi y. J Gastroenterol Hepatol. 2017 Aug;32(8):1495-1502. doi: 10.1111/jgh.13743. J Gastroenterol Hepatol. 2017. PMID: 28109022
12 results